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Abstract
Obesity is a multifactorial disorder with high heritability (50–75%), which is probably higher
in early-onset and severe cases. Although rare monogenic forms and several genes and
regions of susceptibility, including copy number variants (CNVs), have been described, the
genetic causes underlying the disease still remain largely unknown. We searched for rare
CNVs (>100kb in size, altering genes and present in <1/2000 population controls) in 157
Spanish children with non-syndromic early-onset obesity (EOO: body mass index >3 stan-
dard deviations above the mean at <3 years of age) using SNP array molecular karyotypes.
We then performed case control studies (480 EOO cases/480 non-obese controls) with the
validated CNVs and rare sequence variants (RSVs) detected by targeted resequencing of
selected CNV genes (n = 14), and also studied the inheritance patterns in available first-
degree relatives. A higher burden of gain-type CNVs was detected in EOO cases versus
controls (OR = 1.71, p-value = 0.0358). In addition to a gain of the NPY gene in a familial
case with EOO and attention deficit hyperactivity disorder, likely pathogenic CNVs included
gains of glutamate receptors (GRIK1, GRM7) and the X-linked gastrin-peptide receptor
(GRPR), all inherited from obese parents. Putatively functional RSVs absent in controls
were also identified in EOO cases at NPY, GRIK1 and GRPR. A patient with a heterozygous
deletion disrupting two contiguous and related genes, SLCO4C1 and SLCO6A1, also had
a missense RSV at SLCO4C1 on the other allele, suggestive of a recessive model. The
genes identified showed a clear enrichment of shared co-expression partners with known
genes strongly related to obesity, reinforcing their role in the pathophysiology of the disease.
Our data reveal a higher burden of rare CNVs and RSVs in several related genes in patients
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with EOO compared to controls, and implicate NPY, GRPR, two glutamate receptors and
SLCO4C1 in highly penetrant forms of familial obesity.
Author summary
Although there is strong evidence for a high genetic component of obesity, the underlying
genetic causes are largely unknown, mostly due to the highly heterogeneous nature of the
disorder. In this work, we have focused on the most severe end of the spectrum, severe
obesity with early-onset in childhood, which is more likely due to genetic alterations. We
screened for rare copy number variation (CNV) a sample of 157 Spanish children with
early-onset obesity using molecular karyotypes and then studied the genes altered by
CNVs in 480 cases and 480 non-obese controls. We identified a higher burden of gain-
type CNVs in cases as well as several CNVs and sequence variants that were specific of the
obese population. Interestingly, the genes identified shared co-expression partners with
known obesity genes. Among those, the genes encoding the neuropeptide Y (NPY), two
glutamate receptors (GRIK1, GRM7), the X-linked gastrin-peptide receptor (GRPR), and
the organic anion transporter (SLCO4C1) are novel obesity candidate genes that may con-
tribute to highly penetrant forms of familial obesity.
Introduction
Early-onset overweight (body mass index [BMI] 85th percentile for age and sex) and obesity
(BMI 95th percentile for age and sex) currently affects 27.8% of children in Spain (Spanish
National Health Survey, 2011–2012), being the most prevalent chronic disorder in childhood
and adolescence. In the United States, 17.3% of children aged 2 to 19 years are obese, 5.9%
meet criteria for class 2 obesity (BMI 120% of the 95th percentile or BMI 35), and 2.1%
have class 3 obesity (BMI 140% of the 95th percentile or BMI 40) [1]. Early-onset obesity
(EOO) entails several comorbidities and predisposes to obesity and related diseases during
adulthood, being one of the most important health problems in developed countries.
Single gene alterations with Mendelian inheritance account for less than 5% of non-syndro-
mic cases of severe EOO [2], including mutations in the LEP (MIM 164160) or LEPR (MIM
601007) genes [3–5], as well as in MC4R (MIM 155541) [6,7] which are the most common
cause of monogenic obesity. Genetic, genomic and epigenetic alterations have also been identi-
fied in syndromic forms of obesity, such as Bardet-Biedl syndrome (MIM 209900) [8], Prader-
Willi syndrome (MIM 176270) [9], Beckwith-Wiedemann syndrome (MIM 130650) [10] and
other rare diseases. However, obesity is generally considered a multifactorial disorder with
high heritability (50–75%), probably higher in early-onset cases [11]. To date multiple studies
have tried to elucidate genetic factors contributing to the etiopathogenesis of obesity, and rele-
vant SNPs in more than 100 loci have been identified by Genome Wide Association Studies
(GWAS), including those near genes such as FTO (MIM 610966), MC4R, NEGR1 (MIM
613173) or TMEM18 (MIM 613220) [12–15]. Nevertheless, the fraction of BMI variance
explained by these GWAS top hits is estimated to be only around 2% [16]. Even the infinitesi-
mal model, that combines the effect of all common autosomal SNPs, only explains *17% of
the variance in BMI [17]. Gene-based meta-analysis of GWAS allowed the identification of
regions with high allelic heterogeneity and new loci involved in obesity [18,19].
Novel genes in severe early-onset obesity
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In addition, several common and rare copy number variants (CNV) contributing to the
heritability of BMI and obesity have been reported, including deletions upstream of the
NEGR1 gene [13], proximal and distal deletions at 16p11.2 [20], gains at 10q26.6 containing
the CYP2E1 gene (MIM 124040) [21], and homozygous deletions at 11q11 encompassing
olfactory receptor genes [22], among others. While several studies in large datasets led to the
conclusion that common CNVs are not a major contributor [22], a significantly increased bur-
den of rare CNVs was documented in cases of severe obesity with and without associated
developmental delay [15,23]. Specifically, a significant enrichment for CNVs larger than 100
Kb and with a population frequency lower than 1% was identified in subjects with isolated
severe EOO when compared to controls [15].
In the present study, we have analyzed the contribution to the phenotype of rare and com-
mon CNVs as well rare sequence variants (RSVs) in CNV-related genes in a large Spanish
sample of patients with isolated severe EOO using case-control and family-based approaches,
with the goal to identify novel genes involved in the pathophysiology of severe obesity.
Results
We used a sequential strategy to identify genes potentially related to EOO through the analysis
of CNVs by molecular karyotyping and subsequent mutation screening using a DNA pooled
approach in a subset of selected genes. The strategy, including the samples used for each step,
is summarized in Fig 1.
CNV burden in EOO
A total of 42 autosomal CNVs fulfilling the established criteria (>100 kb, gene containing and
present in<1/2000 population individuals) were identified in 36 cases (22.9%). We detected 7
deletions and 35 gains (100.1–3,590kb in length), with 5 samples harboring more than one
rearrangement (Table 1). MLPA was used for validation (42/42) and determination of the
Fig 1. Workflow of the approach followed to study CNVs and RSVs in a subset of selected genes. The different control cohorts used for each of
the analysis are shown, in addition to the number of obese patients and controls studied in each step.
https://doi.org/10.1371/journal.pgen.1006657.g001
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Table 1. Summary of copy number variations detected in 157 samples of patients with severe obesity. Control frequency refers to the frequency of
the same type of rearrangement, deletion or duplication, in the control cohort (9,820 subjects). Progenitor phenotype refers only to the progenitor carrying the
alteration. Hg19 assembly. F: female; M: male; Mat: maternal; Pat: paternal; N: normal; OW: overweight; OB: obesity; NA: not available; +: description of a
mouse model with a phenotype related to body mass index (S1 Table). The genes interrupted at any of the breakpoints of the CNV are shown in boldface.
Case Gender Gain/
Loss
Region Length
(kb)
Hg19 coordinates Genes Inheritance Progenitor
phenotype
Control
frequency
Mouse
model
Recurrent alterations in obese patients
Ob_1 F Gain 9q34.3 149 chr9:138149166–
138298164
C9orf62 Mat N 1
Ob_2 F Gain 9q34.3 139 chr9:138149166–
138288052
C9orf62 Pat OW 1
Ob_3 F Gain 9q34.3 139 chr9:138149166–
138288052
C9orf62 Mat OW 1
Ob_4 M Gain 7p22.1 106 chr7:5785086–
5891221
RNF216,ZNF815 Mat OB 4
Ob_5 F Gain 7p22.1 106 chr7:5785086–
5891221
RNF216,ZNF815 Pat OB 4
Ob_6 F Loss 11p15.4 104 chr11:4583029–
4687238
TRIM68 and 5 more
genes
Pat OB 2
Obese specific alterations, not found in 10,320 controls, co-segregating with the phenotype in the family
Ob_7 F Gain 3q29 1169 chr3:196533320–
197701913
DLG1,PAK2,LMLN
and 10 more genes
Mat OB 0 +
Ob_8 F Gain 4q12 361 chr4:53842714–
54203701
SCFD2 Pat OB 0
Ob_9 F Loss 6q23.2 166 chr6:133386327–
133552737
LINC00326 Mat OB 0
Ob_10 M Loss 5q21.1 157 chr5:101620174–
101776835
SLCO4C1,SLCO6A1 Pat OB 0
Ob_11 M Gain 7p15.3 202 chr7:21858215–
22059791
CDCA7L,DNAH11 Pat OB 0
Ob_12 M Gain 7p15.3 137 chr7:24258773–
24395900
NPY Mat OB 0 +
Ob_13 F Gain 10p14 1029 chr10:10743956–
11773389
CELF2 and 4 more
genes
Mat OB 0
Ob_14 M Gain 14q31.1 105 chr14:81204951–
81309536
CEP128 Mat OB 0
Ob_15 F Gain 14q31.3 274 chr14:89171711–
89445350
EML5,TTC8 Mat OB 0 +
Ob_16 M Gain 19p13.3 428 chr19:2221792–
2650034
AMH,DOT1L,GNG7
and 14 more genes
Pat OB 0
Ob_17 M Gain 20p12.1 220 chr20:13255679–
13476090
ISM1,TASP1 Pat OB 0 +
Copy number variations detected in single cases
Ob_18 F Gain 1p36.13 223 chr1:17202355–
17425829
ATP13A2,PADI2 and
3 more genes
Mat N 0
Ob_19 M Gain 1p31.3 405 chr1:61704166–
62109502
NFIA Mat OW 3
Ob_20 M Gain 2q24.1 336 chr2:159176303–
159512667
CCDC148,PKP4 Mat N 0
Ob_21 M Gain 3p26.1 214 chr3:4272253–
4486303
SETMAR,SUMF1 Pat N 2
Ob_22 M Gain 3p26.1 364 chr3:7660133–
8024019
GRM7 Mat OW 3
Ob_15 F Loss 3q12.3 3590 chr3:101816344–
105406145
ZPLD1, ALCAM,
CBLB
De novo - 0
(Continued )
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inheritance pattern (41/42): all tested rearrangements were inherited except for the larger dele-
tion. We also detected and validated 2 additional CNVs on the X-chromosome for a total of 44
CNVs.
Clinical data about the parental phenotype was available in all but two families with CNVs.
The progenitor harboring the CNV was obese (defined as BMI >30) in 21 cases (53.8%), was
overweight (BMI 25–30) in 7 cases (17.9%) and had a BMI in the normal range in 11 cases
Table 1. (Continued)
Case Gender Gain/
Loss
Region Length
(kb)
Hg19 coordinates Genes Inheritance Progenitor
phenotype
Control
frequency
Mouse
model
Ob_23 M Gain 4q13.3 101 chr4:71055318–
71156301
C4orf7,CSN3,ODAM Mat N 0
Ob_18 F Gain 5p15.33 295 chr5:303686–598237 AHRR,PDCD6, and 6
more
Mat OW 3
Ob_24 M Gain 5q35.3 397 chr5:179220638–
179617799
C5orf45,RASGEF1C
and 6 more
Pat N 0
Ob_25 M Gain 6q15 445 chr6:89349438–
89793993
PNRC1,RNGTT Mat OW 0
Ob_26 F Gain 7p14.1 105 chr7:40117098–
40221714
C7orf10,C7orf11,
CDK13
Pat OB 1
Ob_27 F Gain 9p24.3 448 chr9:396232–844001 DMRT1,DOCK8,
KANK1
Mat N 2
Ob_15 F Loss 10q21.3 156 chr10:69418270–
69574169
CTNNA3,DNAJC12 Mat OB 1
Ob_28 M Gain 11p13 129 chr11:32986850–
33116054
CSTF3,QSER1 and 3
more genes
Pat N 0
Ob_29 F Gain 12q23.3 116 chr12:104476277–
104591886
HCFC2,NFYB Pat NA 0
Ob_30 M Gain 12q24.33 218 chr12:131620578–
131838842
GPR133,LOC116437 Pat OB 1
Ob_16 M Gain 15q25.2 418 chr15:84414592–
84832932
ADAMTSL3,
EFTUD1P1
Pat OB 1
Ob_31 M Gain 17q23.1 248 chr17:58113570–
58361461
CA4,USP32 and 5
more genes
NA NA 0
Ob_32 F Gain 18p11.31 245 chr18:6308208–
6553040
L3MBTL4,
LOC100130480,
MIR4317
Mat OW 0
Ob_5 F Gain 18p11.21 262 chr18:12917703–
13180058
CEP192,SEH1L Mat N 2
Ob_14 M Gain 20p12.1 204 chr20:13867165–
14070869
MACROD2,SEL1L2 Pat N 0
Ob_33 F Gain 21q21.3 163 chr21:31280603–
31443375
GRIK1 Pat OB 1 +
Ob_34 F Loss 22q11.22 261 chr22:22312292–
22573637
TOP3B Pat OB 2
Ob_35 F Loss 22q11.22 676 chr22:22981587–
23657613
BCR and 7 more Mat NA 0
Ob_36 M Gain 22q13.33 198 chr22:50342728–
50584201
IL17REL,MLC1,
MOV10L1,PIM3
Pat NA 0
Copy number variations detected in X chromosome
Ob_37 F Gain Xp22.2 305 chrX:15952591–
16257827
GRPR Mat N 1 +
Ob_6 F Gain Xq26.2 369 chrX:130639755–
131008470
LOC286467,OR13H1,
IGSF1
Pat OB 0
https://doi.org/10.1371/journal.pgen.1006657.t001
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(28.2%). More than half of the rare CNVs (25 of 44), 21 gains and 4 deletions, were not found
in any of the 9,820 adult population controls.
In order to analyze the global burden of rare CNVs in EOO, we compared the amount, type
and length of autosomal CNVs in patients (157) with respect to 500 Spanish population con-
trols (Table 2). Rare CNVs were found in 15.8% of controls with respect to the 22.9% fre-
quency found in patients (p = 0.053). Rare CNVs were predominantly gains in both cohorts
(83.3% in EOO patients and 77.6% in controls). When the frequency of deletions and gains
was analyzed separately, no differences were observed in deletion-type CNVs (3.8% in controls
and 4.5% in patients), while a statistically significant difference in the frequency of gains was
detected (p = 0.0358). Thus, there is a higher burden of CNVs in EOO patients due to rare
gain-type CNVs.
If we consider specific CNVs as those not described in the initial 9,820 subjects used to
establish the frequency of each alteration in the population, 8.2% control individuals carried a
CNV fulfilling this criteria while the frequency was 14.0% in EOO patients, with this difference
being statistically significant (p = 0.0422).
Regarding the co-occurrence of more than one CNV in the same subject, two or three hits
were present in 3.2% patients and 1% controls. This difference was not statistically significant
(p = 0.0644) likely due to the small sample size. The inheritance pattern of these alterations
was established in patients; in two cases each alteration was inherited from a different parent
and in the remaining three both rearrangements were inherited from the same progenitor.
Case Ob_15 presented a third de novo event additionally to the two rearrangements inherited
from her obese mother.
Potentially pathogenic CNVs
CNVs were considered to have a higher probability to be pathogenic when they were exclusive
of the EOO population, co-segregated with the phenotype in the family, disrupted known
genes for the disorder and/or were found in more than one case.
Nine duplications and two deletions were absent in 9,820 population controls and co-segre-
gated with the phenotype in the family (Table 1). One of them was a 137kb gain in 7p15.3 con-
taining a single coding gene, NPY (MIM 162640), identified in a male case (Ob_12) presenting
with EOO and attention deficit hyperactivity disorder (ADHD) (Fig 2A). The CNV was inher-
ited from the also obese mother (Fig 2B). Additional cases of severe EOO and ADHD were
identified in the maternal branch of this family by report (Fig 2C), but unfortunately no addi-
tional samples or clinical data could be obtained.
Some CNVs overlapped with previously described microdeletion/microduplication syn-
dromes (Table 1). Rearrangements partially overlapping with the critical region of the 22q11.2
distal deletion syndrome were identified in two patients. Ob_35 carried a 676kb deletion
encompassing several genes including RSPH14 (MIM 605663) and GNAZ (MIM 139160),
while a more proximal deletion including TOP3B (MIM 603582) was detected in Ob_34. A
Table 2. Comparisons of the frequency of rare copy number changes in autosomal chromosomes >100kb detected in the patient cohort and in the
cohort of 500 controls. In brackets the proportion of samples with the CNV and the proportion of the specific type of rearrangement.
Group Alterations Deletions Duplications Double hit Samples
Controls
(500)
85 19 (3.8% / 22.4%) 66 (12.6% / 77.6%) 5 (1.0%) 79 (15.8%)
Obese patients (157) 42 7 (4.5% / 16.7%) 35* (19.7% / 83.3%) 5 (3.2%) 36 (22.9%)
* p-value<0.05
https://doi.org/10.1371/journal.pgen.1006657.t002
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gain of 348kb at 1q21.1 overlapping with the region of Thrombocytopenia-Absent Radius syn-
drome (MIM 274000) was detected in case Ob_39; as its frequency in controls was 1/1,720 it
was not included in the subset of selected CNVs.
Two CNVs fulfilling the established criteria were identified in more than one patient
(Table 1). A gain of 139kb in 9q34.3 only including C9orf62was found in three cases (Ob_1,
Ob_2, Ob_3). However, the parents also carrying the CNV had either overweight or normal
weight. Another gain of 106kb in 7p22.1 encompassing RNF216 (MIM 609948) and ZNF815P
was identified in two cases (Ob_4, Ob_5), inherited from obese parents. We then completed
the analysis of the CNVs identified in the entire sample of obese individuals (n = 480) and the
Spanish adult non-obese controls (n = 480) by MLPA. All rare CNVs were patient-specific
except for a second patient with a deletion at 11p15.4. None of the rare CNVs were identified
among controls except for the 106kb gain at 7p22.1 that was found in 5 controls. The re-analy-
sis of SNP array data unraveled the complexity of mapping this region due to small segmental
duplications and was used to determine the real frequency of the rearrangement, which was
above the established threshold of the study (1/2,000).
Fig 2. Detection, validation and inheritance of the duplication encompassing NPY in case Ob_12 and his family. A: Ideogram showing the
location of the CNV and the specific genomic interval included in the duplication. The plot shows the results of SNP array with the Log R Ratio
represented by black dots and the B Allele Frequency (BAF) represented by red dots. Hg19 assembly. B: MLPA of the trio showing the maternal
inheritance of the rearrangement represented by a single probe (indicated). C: Pedigree of the family showing several cases with severe obesity, as well
as ADHD (attention-deficit/hyperactivity disorder). The two individuals carrying the duplication are labeled by an *; samples from additional relatives
were not available.
https://doi.org/10.1371/journal.pgen.1006657.g002
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Association study with common CNVs
We also explored more common CNVs already described in association with obesity. The gain
in 10q26.3 including CYP2E1was more common in patients than in controls (6.4% vs 3.6%) as
previously described [21], but did not reach significance (OR: 2.01, CI95% 0.93–4.36, p-
value = 0.075). The frequency of the homozygous deletion encompassing olfactory receptors
in 11q11 was 5.1% in cases, which was slightly lower than the frequency in the control cohort
(6.7%). Therefore, our data did not replicate the previous findings that indicate a preferable
transmission of the 11q11 deletion to obese children [22]. In addition, in this study we did not
detect alterations in the 16p11.2 region, including or next to the SH2B1 (MIM 608937) gene.
Identification of RSVs in novel genes by targeted capture sequencing of
pooled DNA
All genes included and/or disrupted by CNVs found in more than one patient and/or co-segre-
gating in a familial case were selected for sequence analysis (n = 14): SCFD2,NPY, ISM1 (MIM
615793), TASP1 (MIM 608270), GRM7, LOC401164,TRIML1, SLCO4C1, SLCO6A1,C11orf40,
TRIM68 (MIM 613184), GRIK1, TOP3B and GRPR. In order to sequence the total number of
patients (480) and controls (480) in a cost-efficient manner, pools of 20 DNA samples were
sequenced with each DNA sample located in two pools.
We first validated the suitability and specificity of the pipeline to detect real variants among
the pools. RSVs were considered when they had a frequency below 1/1.000 in the public data-
base of the Exome Sequencing Consortium (ExAC) representing more than 60,000 exomes
[24]. We selected 23 alterations predicted to be in a single sample and reanalyzed the same
sample by Sanger sequencing. All 23 RSVs were validated in the specific samples.
We then compared the total burden of RSVs per gene between patients and controls. Signif-
icant differences were identified in a few loci, namely NPY, GRIK1 (MIM 138245) and GRPR
(MIM 305670) (Table 3). A single missense RSV in NPY (p.V86D) was identified in patient
Ob_158, while no RSVs of this gene were found in controls. Although the residue is not evolu-
tionarily conserved and is located outside the main functional domain, the change is likely to
affect the shape and the affinity of the NPY protein and has not been described in ExAC. The
study of parental samples revealed that the RSV was inherited from the obese father (BMI 34.3
kg/m2). The low frequency of missense variants in this gene in the ExAC database (only 27
among 118.884 alleles) further reinforces its functional relevance.
A nonsense mutation (p.R897X) was identified in GRIK1, encoding the ionotropic gluta-
mate receptor 1, in patient Ob_163. This nonsense variant has a frequency below 1/15000
Table 3. Point mutations detected by pooled DNA sequencing in the cohort of 480 patients. Control frequency refers to the allele frequency of the
same variant in the subjects included in the ExAC database (60,706 unrelated individuals). Progenitor phenotype refers only to the progenitor carrying the
alteration. Hg19 assembly. F: female; M: male; Mat: maternal; Pat: paternal; NA: not available.
Gene name Variant cDNA level Protein level Phylo P Control frequency Case Gender Inheritance Progenitor phenotype
NPY chr7:24329186 c.T257A p.V86D 0.798641 0 Ob_158 F Pat Obesity
GRPR chrX:16142093 c.G17C p.C6S 0.992202 0.00095 Ob_159 F NA NA
GRPR chrX:16142335 c.C259A p.L87M 0.948124 0.00097 Ob_160 M Mat Obesity
GRPR chrX:16170380 c.T767C p.I256T 0.997201 0 Ob_161 F NA NA
GRPR chrX:16168672 c.G658A p.V220I 0.787201 0.00049 Ob_38 F NA NA
Ob_162 M Mat Normal
GRIK1 chr21:30909580 c.C2689T p.R897X 0.999731 0.00006 Ob_163 M NA NA
SLCO4C1 chr5:101606433 c.A697C p.I233L 0.974709 0 Ob_10 M Mat Normal
https://doi.org/10.1371/journal.pgen.1006657.t003
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alleles and, generally, nonsense and frameshift variants at the GRIK1 gene are rare, represent-
ing less than 1/3000 alleles in the ExAC database. Additional missense mutations were identi-
fied in both glutamate receptors (GRIK1 and GRM7 (MIM 604101)), but with no significant
differences between cases and controls.
Four different missense mutations were detected in GRPR in five patients with obesity,
while no mutations in this gene were found in controls (5/662 alleles vs 0/726 alleles;
p = 0.0245). One of the mutations has never been found in ExAC, while the remaining three
had frequencies <1/1000 alleles and all are predicted to result in significant functional
consequences.
Finally, a RSV in SLCO4C1 (MIM 609013) was identified in a patient harboring a deletion
encompassing the same gene previously identified by CMA. The RSV (p.I233L) has not been
described previously and affects a highly conserved amino acid (phylo P = 0.975). The fre-
quency of the deletion in the control cohort is 0/9,820. Parental studies confirmed that each
progenitor had transmitted one of the alterations; the deletion was inherited from the obese
father and the RSV from the non-obese mother. These findings are compatible with a recessive
pattern of inheritance or a two-hit mechanism, with a major contribution of the CNV (inher-
ited from an obese progenitor) and an additional and milder effect of the RSVs (inherited
from a non-obese progenitor).
Co-expression enrichment analyses
We focused our subsequent analysis on four novel candidate genes considering our CNVs and
RSVs findings: GRIK1, GRM7, GRPR and SLCO4C1. To explore their possible role in obesity,
we looked for co-expressions with a stringent list of 15 genes previously related with obesity.
We selected a total 10 genes with described highly penetrant mutations in severely obese
patients, all of them coding for proteins of the leptin-melanocortin pathway: LEP[4], LEPR[5],
MC4R[6], POMC (MIM 176830) [25], PCSK1 (MIM 162150) [26], MC3R (MIM 155540)
[27,28], BDNF (MIM 113505) [29], NTRK2 (MIM600456) [30], PPARG (MIM 601487) [31]
and SIM1(MIM 603128) [20,32]. We also included 5 additional genes with a relevant interme-
diary role in the same pathway: ADRB3 (MIM 109691) [33], PCSK2 (MIM 162151) [34,35],
NPY[36], NPY1R (MIM 162641) [37], AGRP (MIM 602311) [36,38] (Fig 3A).
A total of 10 shared co-expressed partners were identified in the analysis between our 4
novel strongest candidate genes (GRIK1, GRM7, GRPR and SLCO4C1) and the set of 15 obe-
sity-related genes described in the literature. The maximum number of shared co-expressed
partners between our 4 genes and 500 genes sets randomly selected was 7, being the empirical
p-value of this difference 0.002 (Fig 3B and 3C).
Discussion
Our results reveal a relevant contribution of rare CNVs to the etiology of severe EOO with a
significantly higher burden of gain-type CNVs in patients compared to controls (p = 0.0358).
Among relatively common CNVs we only detected a non-significant higher frequency of the
gain in 10q26.3 containing CYP2E1 [21]. Previous studies reported a higher frequency of dele-
tion-type CNVs in patients with severe EOO with and without developmental delay [23]. The
sample studied here was stringently selected based on clinical exam and targeted genetic test-
ing in order to exclude subjects with syndromic obesity. Thus, all patients presented isolated
EOO without comorbid phenotypes such as developmental delay. This difference in the range
of phenotype severity could explain the difference in the type of rearrangements found
enriched in these cohorts. Although only one of the CNVs had occurred de novo, the progeni-
tor carrying the alteration also presented overweight or obesity in 71.8% of cases, reinforcing
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the potential role of many of these genetic alterations in the pathophysiology of the disorder.
The only de novo alteration (a 3.6Mb deletion encompassing only 3 genes) was detected in a
girl with two additional rearrangements inherited from her obese mother.
We have also screened for point mutations using DNA pools in a subset of selected genes
located in obese-specific CNVs [39]. Interestingly, we found additional RSVs in patients in 4
of the selected genes (NPY, GRPR, SLCO4C1 and GRIK1) reinforcing their putative role in the
pathophysiology of obesity. Although the pooled DNA strategy might have some limitations
such as underdetection of relatively common variants, the complete validation rate (100%)
demonstrates its high specificity.
A maternally inherited gain in 7p15.3 only encompassing the NPY gene was identified in a
patient with EOO and ADHD. The mother also presented severe obesity, as did several rela-
tives from the maternal branch including two male cousins with associated ADHD. Addition-
ally, a missense RSV also inherited from an obese progenitor was identified in another patient,
while no alterations were identified in controls (480). A larger gain of approximately 3Mb on
chromosome 7p15.2–15.3 encompassing NPY and other genes was previously described in all
Fig 3. Enrichment analyses of shared co-expressed partners between 14 known obesity-related genes and the candidate genes from this
study. A: Key players on the regulation of food intake and energy expenditure mostly act through the leptin-melanocortin pathway. B: Shared co-
expressed partners between the four candidate genes (GRIK1, GRM7, GRPR, SLCO4C1) and 500 randomly generated gene sets. The number shared
co-expressed partners of the candidate genes with the 14 obesity-related genes are indicated by a red arrow. C: Co-expression network including the
selected obesity-related genes and GRIK1, GRM7, GRPR, SLCO4C1. This network was visualized using Cytoscape.
https://doi.org/10.1371/journal.pgen.1006657.g003
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affected individuals of an extended pedigree presenting ADHD, increased BMI, and elevated
NPY levels in blood [40]. Therefore, the gain encompassing only the NPY gene in patient
Ob_12 and his obese mother, the point mutation in patient Ob_158 and her obese father while
only 27 missense variants have been described among 118.884 alleles in ExAC are strong evi-
dences supporting that gain of function mutations of NPY can cause severe obesity and
ADHD.
NPY is a hypothalamic orexigenic peptide with neuromodulator functions in the control of
energy balance and food intake. NPY is overproduced in the hypothalamus of leptin deficient
ob/ob mice [41]; when depleted by genetic manipulation, ob/ob mice showed reduced food
intake, increased energy expenditure and less obesity [42]. On the other hand, overexpression
of NPY in noradrenergic neurons caused diet- and stress-induced gain in fat mass in a gene-
dose-dependent fashion [43].
In humans, despite some conflictive reports, NPY gene variants have been significantly
associated with weight changes from young adulthood to middle age and with risk of obesity
[44]. NPY is widely expressed throughout the central nervous system (CNS) and a systematic
review and meta-analyses of drug naïve case-control studies also suggested its implication in
ADHD [45]. In addition, increased central availability of NPY by intracerebroventricular
administration in male rats resulted in a shift of metabolism towards lipid storage and
increased carbohydrate use, along with enhanced locomotor activity and body temperature
[46].
Among other genes altered by the CNVs identified, we considered as probably pathogenic
those exclusive of the EOO population that also presented exclusive RSVs co-segregating with
the phenotype in the family. To further assess the possible implication of these strong candi-
date genes (GRIK1, GRM7, GRPR and SLCO4C1), we determined the co-expression patterns
between them and 15 well-defined genes from the leptin-melanocortin pathway previously
related to obesity. This analysis consistently identified a significant enrichment of co-expres-
sion shared partners among our genes and the subset of obesity related genes when compared
to 500 randomly generated gene sets, reinforcing the possible role of those genes in the patho-
physiology of EOO.
The alterations affecting glutamate receptors identified in two EOO patients were a partial
gain of the gene encoding the ionotropic glutamate receptor GRIK1 (Ob_33) and a gain par-
tially encompassing the gene encoding the metabotropic glutamate receptor GRM7 (Ob_22).
L-glutamate is one of the main excitatory neurotransmitter in the CNS and activates both
ionotropic and metabotropic glutamate receptors. A nonsense mutation was found in an addi-
tional patient in GRIK1. The metabotropic glutamate receptor 5 (mGluR5) plays a relevant
role in energy balance and feeding. Adult mice lacking mGlu5 weighed significantly less than
littermate controls and resisted diet-induced obesity [47]. Pharmacological approaches have
described a reduction of food intake in response to antagonists of mGluR5 in a baboon model
of binge-eating disorder [48] and in mGluR5+/+, but not mGluR5-/- mice [47]. On the con-
trary, dose-dependent stimulation of food intake has been described in rodents after injection
of a mGluR5 agonist [49]. Moreover, the metabolic status and leptin can modify astrocyte-spe-
cific glutamate and glucose transporters, indicating that metabolic signals influence glutama-
tergic synaptic efficacy and glucose uptake [50]. Interestingly, GRM7 is likely a loss of function
intolerant gene given the difference between expected and observed frequency of loss of func-
tion variants in ExAC (25 expected, 1 observed). Partial gains, depending on the location,
might act as loss of function alterations when disrupting the gene. Considering these data, glu-
tamate receptors are promising candidates in the pathophysiology of obesity.
Several alterations affecting GRPR gene were identified, including a gain encompassing the
whole gene and 4 point mutations (present in 5 subjects, two males and three females) while
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none were found in controls. The male patients with hemizygous GRPR RSVs had inherited
the variant from heterozygous mothers. Both patients had very early onset obesity in infancy
presenting a quite severe phenotype at diagnosis (+5SD and +9SD respectively). One of the
mothers (patient Ob_162) had a BMI within the normal range while the other presented adult-
onset obesity. Thus, the phenotype of both males is more severe than the phenotype of their
mothers, consistent with X-linked inheritance. GRPR encodes the receptor of gastrin-releasing
peptide. Gastrin is a hormone secreted by the gastric antrum and duodenum in response to
gastric distension and the presence of food in the stomach. This hormone increases the pro-
duction of hydrochloric acid, pepsinogen, pancreatic secretions and bile to facilitate food
digestion and also promotes satiety [51]. It is a hormone directly implicated in the regulation
of food ingestion and satiety and, thus, a candidate to be associated with obesity (directly or by
an alteration of a gene included in the pathway, such as GRPR).
A possible recessive pattern of inheritance or a double hit mechanism was identified in a
patient who harbors a deletion partially encompassing SLCO4C1 and SLCO6A1 (MIM 613365)
and a RSV in SLCO4C1, each alteration inherited from one of the progenitors. Considering
that the CNV was inherited from an obese progenitor and the RSV from the non-obese
mother, we postulate a major contribution of the CNV and an additional but likely milder
effect of the RSVs. The SLCO4C1 belongs to the organic anion transporter family and is
involved in the membrane transport of thyroid hormones, among others. Interestingly, none
homozygote subjects for loss of function variants has been described in ExAC.
Other rearrangements were found in single EOO patients, including those in regions
previously associated to disease, such as 22q11.2 or 1q21.1. However, the evidence to
link these genomic regions to obesity susceptibility is still weak and further data will be
needed.
Except for the patient with a biallelic alteration in SLCO4C1 and the de novo deletion, all
CNVs and RSVs identified are heterozygous in the patients and inherited from one of the
parents. Parents carrying the allele also showed an obese phenotype as well in most cases.
Thus, a dominant effect (either hypo or hypermorphic) for these rare genetic variants with
additive effects is suggested, leading to a more severe phenotype in the younger generation.
This effect has also been found in other studies [52] and can be due to the more “obeso-
genic” environment that has developed in industrialized societies during the last two
decades. Our results, along with previous genetic, family-based and epidemiologic studies,
further indicate that EOO etiology is complex and mostly multifactorial, with the presence
of some alleles that can behave as highly penetrant susceptibility variants or monogenic
forms of obesity.
In summary, our findings reveal a higher burden of rare CNVs in patients with EOO com-
pared to controls, including novel CNVs likely associated with familial obesity. Dosage sensi-
tive genes altered by these CNVs are candidates for contributing to the pathogenesis of EOO.
Some of these genes also harbor patient-specific RSVs, reinforcing their putative role in the
pathophysiology of obesity. NPY, GRPR, SLCO4C1 and glutamate receptors emerge as novel
candidate genes involved in monogenic familial obesity.
Materials and methods
Subjects
Criteria for severe EOO was a BMI more than three standard deviation measures above the
mean for age and gender with onset earlier than 3 years of age. All cases underwent a detailed
clinical examination as well as family history in search of syndromic forms of obesity, which
were discarded. All studies were performed as part of a research project approved by the
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Medical Ethical Committee of the Hospital Infantil Universitario Niño Jesu´s, after receiving
written informed consent from the family.
Blood samples from patients were collected. Parental blood samples were also collected in
cases in which an alteration was identified. DNA from patients and parents was isolated from
total blood using the Gentra Puregene Blood kit (Qiagen) according to manufacturer’s instruc-
tions. We excluded genomic and epigenetic alterations associated with pseudohypoparathyr-
oidism (MIM 103580), Prader-Willi, Temple (MIM 616222) and Beckwith-Wiedemann
syndromes with a custom-made panel (S2 Table) of Methylation Specific Multiplex Ligation
Dependent-Probe Amplification (MS-MLPA) [53].
A total of 480 unrelated subjects with severe EOO were included in the study. As controls
for CNV and RSV association analyses, we studied 480 adult individuals of Spanish origin
with a current BMI lower than 25 and no known history of childhood obesity, obtained from
the National DNA Bank from the University of Salamanca (Spain).
Molecular karyotyping
An initial sample of 157 probands was studied by using Omni1-Quad (64 subjects) or Omni
Express SNP (93 subjects) platforms, Illumina. Copy number changes were identified using
the PennCNV software with stringent filtering, as previously described [54]. CNVs encom-
passing known genes (RefSeq hg19), longer than 100 kb and with a frequency in control sam-
ples lower than 1/2,000 were selected. The frequency of each CNV in the control population
was determined using 1M Illumina SNP array data of a total of 9,820 samples from two data-
bases: 1) 8,329 individuals previously used as population controls for developmental anomalies
[55] (81.2% of European descent, 2% African, and 16.5% other/mixed ancestry), and 2) 1,491
Spanish adult individuals from the Spanish Bladder Cancer/EPICURO study, which includes
1034 patients with urothelial cell carcinoma of the bladder and 457 hospital-based generally
healthy controls with a mean age of 63.7 years [54]. To determine the frequency of CNV in the
X chromosome, only the Spanish controls were considered, as data from the other cohort was
not available. Given the size of the Spanish control sample (1,491), alterations in the X-chro-
mosome absent in controls or only present in one subject were considered as rare. Briefly, a
Hidden Markov Model (HMM) based on both allele frequencies and total intensity values was
used to identify putative alterations, followed by manual inspection in conjunction with user
guided merging of nearby (<1 Mbp between for arrays with<1 million probes and<200 kbp
for arrays with>1 million probes) calls, which represent a single region broken up by the
HMM, or gaps. All samples on arrays with densities <1M probes were filtered by a maximal
genome-wide LogR ratio standard deviation of 0.25, while the high density 1.2 million probe
WTCCC2 data was filtered using an increased standard deviation cut-off of 0.37. Mosaic alter-
ations were excluded. For the two datasets where the Illumina array mapping corresponded to
build35 (NHGRI), we utilized the autosomal calls generated previously [40] and mapped the
coordinates to build36 using the UCSC LiftOver tool [56].
Estimation of rare CNV burden
In order to compare the global burden of rare CNVs in patients and controls, data from 500
individuals randomly selected from the Spanish Bladder Cancer/EPICURO study and not
included as controls for the CNVs frequency determination [54] were used. For the compari-
son, only CNVs in autosomal chromosomes with a minimum length of 100 kb, altering genes,
and a frequency in control samples lower than 1/2,000 were considered (S3 Table). Alterations
totally overlapping with segmental duplications were excluded to minimize biases due to the
different probe coverage among microarray platforms.
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Multiplex Ligation-Dependent Probe Amplification (MLPA)
An MLPA assay was designed to validate genetic alterations detected by SNP platforms and to
study inheritance in families (available upon request). A total of 100 ng of genomic DNA from
each sample was subject to MLPA using specific synthetic probes (sequence available upon
request) designed to target the specific CNV detected. All MLPA reactions were analyzed on
an ABI PRISM 3100 Genetic analyzer according to manufacturers’ instructions. Each MLPA
signal was normalized and compared to the corresponding peak height obtained in control
samples [57]. The MLPA assay was also used to analyze the frequency of the CNVs identified
in the entire cohort (480 subjects) and in the control population (480 individuals).
Targeted capture sequencing of pooled DNA for RSV identification
To study RSVs in the genes included in the CNVs, an enrichment kit was designed to capture
all the coding regions of the selected genes (n = 14). The targeted enrichment was done with
SeqCap EZ Choice Enrichment Kits (Roche Sequencing) and the massive sequencing with
MiSeq (Illumina).
In order to sequence a high number of patients and controls (960 in total) in a cost-efficient
manner, a pooled DNA approach was used [39]. Each sample was included in two different
pools, and each pool contained 20 samples, avoiding two samples sharing both pools. A priori,
any heterozygous RSV should be present in approximately 1 every 40 reads (2.5%). Thus, to
ensure the identification of all RSVs (expected to be found in just one or few individuals) a
high coverage was required.
To discriminate real variants from false positives due to extremely high coverage, we opti-
mized the analysis pipeline. Variant calling was done with MuTect [58] to detect variants in a
low proportion of reads. We also considered the quality of reads (base quality >15 in each
pool) and the absence of strand bias (between 0.2 and 0.8) to define potential real variants
from false positives.
To analyze the results and compare patients and controls, we focused on RSVs. We first
established the frequency of each variant in the general control population using EXAC as the
reference database, composed of 60,706 unrelated individuals sequenced as part of various dis-
ease-specific and population genetic studies. All alterations present in more than 1/1,000 alleles
in EXAC in any of the populations included in the dataset were excluded. We specially focused
on sequence changes with potential functional consequences, including loss of function vari-
ants (nonsense, frameshift and splice sites), missense variants predicted as pathogenic and
changes in highly conserves residues. To search for recessive patterns of inheritance, we
explored biallelic changes and RSVs that might act as second-hits in patients with previously
identified CNVs.
Sanger sequencing
To validate the RSVs detected by NGS and to define the segregation in each family, we
designed primers to amplify an amplicon encompassing the variant and sequenced the ampli-
con by Sanger technology (available under request).
Co-expression enrichment analyses
Using Genemania, we explored the co-expression between our candidate genes and the selected
subset. To test if there was an enrichment of shared co-expressed partners, 500 sets of 15 genes
with expression data available were randomly selected with Molbiotools (http://www.molbiotools.
com/). For each set of genes the number of shared co-expressed partners was determined and
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compared with the interactions between our candidates and the set of obesity-related genes. The
empirical p-value was calculated based on the fraction of shared co-expressed partners.
Supporting information
S1 Table. Description of mouse models with a phenotype related to body mass index
caused by alterations in genes included in CNVs detected in the patients’ cohort.
(XLSX)
S2 Table. Probes included in the custom-made panel of Methylation Specific Multiplex
Ligation Dependent-Probe Amplification (MS-MLPA) to exclude genomic and epigenetic
alterations associated with pseudohypoparathyroidism, Prader-Willi, Temple and Beck-
with-Wiedemann syndromes.
(XLSX)
S3 Table. CNVs in autosomal chromosomes with a minimum length of 100 kb, altering
genes, and with a frequency in control samples lower than 1/2,000 detected in the control
cohort.
(XLSX)
Acknowledgments
We would like to thank the patients and families for their participation in this study as well as
to Francisca Dı´az for her technical assistance.
Author Contributions
Conceptualization: CSJ GA´MM LAPJ JA.
Data curation: CSJ FBdP JRG BRS.
Formal analysis: CSJ FBdP JRG BRS.
Funding acquisition: LAPJ JA.
Investigation: CSJ FBdP RF GA´MM JA.
Methodology: CSJ LAPJ.
Project administration: CSJ LAPJ JA.
Resources: GA´MM JA.
Software: CSJ FBdP BRS.
Supervision: LAPJ JA.
Validation: CSJ FBdP RF.
Visualization: CSJ FBdP.
Writing – original draft: CSJ GA´MM LAPJ.
Writing – review & editing: JA CSJ GA´MM FBdP RF JRG BRS JA LAPJ.
References
1. Skinner AC, Skelton JA. Prevalence and Trends in Obesity and Severe Obesity Among Children in the
United States, 1999–2012. JAMA Pediatr [Internet]. 2014 Apr 7 [cited 2014 May 23]; 168(6):561–6.
Novel genes in severe early-onset obesity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006657 May 10, 2017 15 / 19
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24710576 https://doi.org/10.1001/jamapediatrics.
2014.21 PMID: 24710576
2. Ranadive SA, Vaisse C. Lessons from extreme human obesity: monogenic disorders. Endocrinol
Metab Clin North Am [Internet]. 2008 Sep [cited 2013 Nov 29]; 37(3):733–51, x. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/18775361 https://doi.org/10.1016/j.ecl.2008.07.003 PMID: 18775361
3. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on
obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital
leptin deficiency. J Clin Invest [Internet]. 2002 Oct [cited 2013 Nov 27]; 110(8):1093–103. Available
from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=150795&tool=
pmcentrez&rendertype=abstract https://doi.org/10.1172/JCI15693 PMID: 12393845
4. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin defi-
ciency is associated with severe early-onset obesity in humans. Nature [Internet]. 1997 Jun 26 [cited
2013 Nov 20]; 387(6636):903–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9202122 https://
doi.org/10.1038/43185 PMID: 9202122
5. Cle´ment K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, et al. A mutation in the human leptin
receptor gene causes obesity and pituitary dysfunction. Nature [Internet]. 1998 Mar 26 [cited 2016 Nov
23]; 392(6674):398–401. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9537324 https://doi.org/
10.1038/32911 PMID: 9537324
6. Farooqi IS, Keogh JM, Yeo GSH, Lank EJ, Cheetham T, O’Rahilly S. Clinical spectrum of obesity and
mutations in the melanocortin 4 receptor gene. N Engl J Med [Internet]. 2003 Mar 20 [cited 2013 Nov
22]; 348(12):1085–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12646665 https://doi.org/
10.1056/NEJMoa022050 PMID: 12646665
7. Granell S, Serra-Juhe´ C, Martos-Moreno GA´ , Dı´az F, Pe´rez-Jurado L a, Baldini G, et al. A novel mela-
nocortin-4 receptor mutation MC4R-P272L associated with severe obesity has increased propensity to
be ubiquitinated in the ER in the face of correct folding. PLoS One [Internet]. 2012; 7(12):e50894. Avail-
able from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3520997&tool=
pmcentrez&rendertype=abstract https://doi.org/10.1371/journal.pone.0050894 PMID: 23251400
8. Katsanis N, Ansley SJ, Badano JL, Eichers ER, Lewis RA, Hoskins BE, et al. Triallelic inheritance in
Bardet-Biedl syndrome, a Mendelian recessive disorder. Science [Internet]. 2001 Sep 21 [cited 2013
Nov 19]; 293(5538):2256–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11567139 https://doi.
org/10.1126/science.1063525 PMID: 11567139
9. Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M. Genetic imprinting suggested by maternal het-
erodisomy in nondeletion Prader-Willi syndrome. Nature [Internet]. 1989 Nov 16 [cited 2013 Nov 28];
342(6247):281–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2812027 https://doi.org/10.
1038/342281a0 PMID: 2812027
10. Ramesar R, Babaya M, Viljoen D. Molecular investigation of familial Beckwith-Wiedemann syndrome: a
model for paternal imprinting. Eur J Hum Genet [Internet]. 1993 Jan [cited 2013 Nov 28]; 1(2):109–13.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/8055321 PMID: 8055321
11. Llewellyn CH, Trzaskowski M, Plomin R, Wardle J. Finding the missing heritability in pediatric obesity:
the contribution of genome-wide complex trait analysis. Int J Obes (Lond) [Internet]. 2013 Mar 26 [cited
2013 Nov 11]; 37(11):1506–9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=3826033&tool=pmcentrez&rendertype=abstract
12. Meyre D, Delplanque J, Chèvre J-C, Lecoeur C, Lobbens S, Gallina S, et al. Genome-wide association
study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat
Genet [Internet]. 2009 Feb [cited 2013 Nov 27]; 41(2):157–9. Available from: http://www.ncbi.nlm.nih.
gov/pubmed/19151714 https://doi.org/10.1038/ng.301 PMID: 19151714
13. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, et al.
Genome-wide association yields new sequence variants at seven loci that associate with measures of
obesity. Nat Genet [Internet]. 2009 Jan [cited 2013 Nov 22]; 41(1):18–24. Available from: http://www.
ncbi.nlm.nih.gov/pubmed/19079260 https://doi.org/10.1038/ng.274 PMID: 19079260
14. Willer CJ, Speliotes EK, Loos RJF, Li S, Lindgren CM, Heid IM, et al. Six new loci associated with body
mass index highlight a neuronal influence on body weight regulation. Nat Genet [Internet]. 2009 Jan
[cited 2013 Nov 10]; 41(1):25–34. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=2695662&tool=pmcentrez&rendertype=abstract https://doi.org/10.1038/ng.287 PMID: 19079261
15. Wheeler E, Huang N, Bochukova EG, Keogh JM, Lindsay S, Garg S, et al. Genome-wide SNP and
CNV analysis identifies common and low-frequency variants associated with severe early-onset obe-
sity. Nat Genet [Internet]. 2013 May [cited 2013 Nov 6]; 45(5):513–7. Available from: http://www.ncbi.
nlm.nih.gov/pubmed/23563609 https://doi.org/10.1038/ng.2607 PMID: 23563609
16. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses
of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet [Internet]. 2010
Nov [cited 2013 Nov 9]; 42(11):937–48. Available from: http://www.pubmedcentral.nih.gov/
Novel genes in severe early-onset obesity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006657 May 10, 2017 16 / 19
articlerender.fcgi?artid=3014648&tool=pmcentrez&rendertype=abstract https://doi.org/10.1038/ng.686
PMID: 20935630
17. Yang J, Manolio TA, Pasquale LR, Boerwinkle E, Caporaso N, Cunningham JM, et al. Genome parti-
tioning of genetic variation for complex traits using common SNPs. Nat Genet [Internet]. 2011 Jun [cited
2014 May 26]; 43(6):519–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21552263 https://
doi.org/10.1038/ng.823 PMID: 21552263
18. Pei Y-F, Zhang L, Liu Y, Li J, Shen H, Liu Y-Z, et al. Meta-analysis of genome-wide association data
identifies novel susceptibility loci for obesity. Hum Mol Genet [Internet]. 2014 Feb 1 [cited 2016 Jul 25];
23(3):820–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24064335 https://doi.org/10.1093/
hmg/ddt464 PMID: 24064335
19. Ha¨gg S, Ganna A, Van Der Laan SW, Esko T, Pers TH, Locke AE, et al. Gene-based meta-analysis of
genome-wide association studies implicates new loci involved in obesity. Hum Mol Genet [Internet].
2015 Dec 1 [cited 2016 Jul 25]; 24(23):6849–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
26376864 https://doi.org/10.1093/hmg/ddv379 PMID: 26376864
20. Walters RG, Jacquemont S, Valsesia A, de Smith AJ, Martinet D, Andersson J, et al. A new highly pene-
trant form of obesity due to deletions on chromosome 16p11.2. Nature [Internet]. 2010 Feb 4 [cited
2013 Nov 7]; 463(7281):671–5. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=2880448&tool=pmcentrez&rendertype=abstract https://doi.org/10.1038/nature08727 PMID:
20130649
21. Yang T-L, Guo Y, Shen H, Li J, Glessner JT, Qiu C, et al. Copy number variation on chromosome
10q26.3 for obesity identified by a genome-wide study. J Clin Endocrinol Metab [Internet]. 2013 Jan
[cited 2013 Nov 27]; 98(1):E191–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23175694
https://doi.org/10.1210/jc.2012-2751 PMID: 23175694
22. Jarick I, Vogel CIG, Scherag S, Scha¨fer H, Hebebrand J, Hinney A, et al. Novel common copy number
variation for early onset extreme obesity on chromosome 11q11 identified by a genome-wide analysis.
Hum Mol Genet [Internet]. 2011 Feb 15 [cited 2013 Nov 27]; 20(4):840–52. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=3024044&tool=pmcentrez&rendertype=abstract
https://doi.org/10.1093/hmg/ddq518 PMID: 21131291
23. Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, et al. Large, rare chromo-
somal deletions associated with severe early-onset obesity. Nature [Internet]. 2010 Feb 4 [cited 2013
Nov 12]; 463(7281):666–70. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=3108883&tool=pmcentrez&rendertype=abstract https://doi.org/10.1038/nature08689 PMID:
19966786
24. Exome Aggregation Consortium (ExAC). No Title [Internet]. [cited 2016 Jun 1]. Available from: http://
exac.broadinstitute.org
25. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gru¨ters A. Severe early-onset obesity, adrenal
insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet [Internet].
1998 Jun [cited 2016 Nov 23]; 19(2):155–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
9620771 https://doi.org/10.1038/509 PMID: 9620771
26. Jackson RS, Creemers JWM, Ohagi S, Raffin-Sanson M-L, Sanders L, Montague CT, et al. Obesity
and impaired prohormone processing associated with mutations in the human prohormone convertase
1 gene. Nat Genet [Internet]. 1997 Jul [cited 2016 Nov 23]; 16(3):303–6. https://doi.org/10.1038/
ng0797-303 PMID: 9207799
27. Lee Y-S, Poh LK-S, Loke K-Y. A Novel Melanocortin 3 Receptor Gene (MC3R) Mutation Associated
with Severe Obesity. J Clin Endocrinol Metab [Internet]. 2002 Mar [cited 2016 Nov 23]; 87(3):1423–6.
https://doi.org/10.1210/jcem.87.3.8461 PMID: 11889220
28. Mencarelli M, Dubern B, Alili R, Maestrini S, Benajiba L, Tagliaferri M, et al. Rare melanocortin-3 recep-
tor mutations with in vitro functional consequences are associated with human obesity. Hum Mol Genet
[Internet]. 2011 Jan 15 [cited 2016 Nov 23]; 20(2):392–9. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/21047972 https://doi.org/10.1093/hmg/ddq472 PMID: 21047972
29. Gray J, Yeo GSH, Cox JJ, Morton J, Adlam A-LR, Keogh JM, et al. Hyperphagia, Severe Obesity,
Impaired Cognitive Function, and Hyperactivity Associated With Functional Loss of One Copy of the
Brain-Derived Neurotrophic Factor (BDNF) Gene. Diabetes [Internet]. 2006 Dec 1 [cited 2016 Nov 23];
55(12):3366–71. https://doi.org/10.2337/db06-0550 PMID: 17130481
30. Yeo GSH, Connie Hung C-C, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, et al. A de novo muta-
tion affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci [Inter-
net]. 2004 Nov [cited 2016 Nov 23]; 7(11):1187–9. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/15494731 https://doi.org/10.1038/nn1336 PMID: 15494731
31. Ristow M, Mu¨ller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a
genetic regulator of adipocyte differentiation. N Engl J Med [Internet]. 1998 Oct 1 [cited 2013 Nov 27];
Novel genes in severe early-onset obesity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006657 May 10, 2017 17 / 19
339(14):953–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9753710 https://doi.org/10.1056/
NEJM199810013391403 PMID: 9753710
32. Michaud JL, Boucher F, Melnyk A, Gauthier F, Goshu E, Le´vy E, et al. Sim1 haploinsufficiency causes
hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum Mol Genet
[Internet]. 2001 Jul 1 [cited 2016 Nov 23]; 10(14):1465–73. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/11448938 PMID: 11448938
33. Mantzoros CS, Qu D, Frederich RC, Susulic VS, Lowell BB, Maratos-Flier E, et al. Activation of beta(3)
adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food
intake in mice. Diabetes [Internet]. 1996 Jul [cited 2016 Nov 23]; 45(7):909–14. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/8666142 PMID: 8666142
34. Ohagi S, LaMendola J, LeBeau MM, Espinosa R, Takeda J, Smeekens SP, et al. Identification and
analysis of the gene encoding human PC2, a prohormone convertase expressed in neuroendocrine tis-
sues. Proc Natl Acad Sci U S A [Internet]. 1992 Jun 1 [cited 2016 Nov 24]; 89(11):4977–81. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/1594602 PMID: 1594602
35. Furuta M, Carroll R, Martin S, Swift HH, Ravazzola M, Orci L, et al. Incomplete processing of proinsulin
to insulin accompanied by elevation of Des-31,32 proinsulin intermediates in islets of mice lacking active
PC2. J Biol Chem [Internet]. 1998 Feb 6 [cited 2016 Nov 24]; 273(6):3431–7. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/9452465 PMID: 9452465
36. Baver SB, Hope K, Guyot S, Bjorbaek C, Kaczorowski C, O’Connell KMS. Leptin Modulates the Intrinsic
Excitability of AgRP/NPY Neurons in the Arcuate Nucleus of the Hypothalamus. J Neurosci [Internet].
2014 Apr 16 [cited 2016 Nov 23]; 34(16):5486–96. https://doi.org/10.1523/JNEUROSCI.4861-12.2014
PMID: 24741039
37. Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor cou-
ples to two different second messenger systems. Proc Natl Acad Sci U S A [Internet]. 1992 Jul 1 [cited
2016 Nov 24]; 89(13):5794–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1321422 PMID:
1321422
38. Chai B-X, Pogozheva ID, Lai Y-M, Li J-Y, Neubig RR, Mosberg HI, et al. Receptor−Antagonist Interac-
tions in the Complexes of Agouti and Agouti-Related Protein with Human Melanocortin 1 and 4 Recep-
tors †, ‡. Biochemistry [Internet]. 2005 Mar [cited 2016 Nov 23]; 44(9):3418–31. https://doi.org/10.1021/
bi0478704 PMID: 15736952
39. Wang SR, Carmichael H, Andrew SF, Miller TC, Moon JE, Derr MA, et al. Large-scale pooled next-gen-
eration sequencing of 1077 genes to identify genetic causes of short stature. J Clin Endocrinol Metab
[Internet]. 2013 Aug [cited 2016 Jul 29]; 98(8):E1428–37. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/23771920 https://doi.org/10.1210/jc.2013-1534 PMID: 23771920
40. Lesch K-P, Selch S, Renner TJ, Jacob C, Nguyen TT, Hahn T, et al. Genome-wide copy number varia-
tion analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in
an extended pedigree. Mol Psychiatry [Internet]. 2011 May [cited 2013 Nov 28]; 16(5):491–503. Avail-
able from: http://www.ncbi.nlm.nih.gov/pubmed/20308990 https://doi.org/10.1038/mp.2010.29 PMID:
20308990
41. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, et al. The role of neuro-
peptide Y in the antiobesity action of the obese gene product. Nature [Internet]. 1995 Oct 12 [cited 2013
Nov 28]; 377(6549):530–2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7566151 https://doi.
org/10.1038/377530a0 PMID: 7566151
42. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss
of neuropeptide Y. Science [Internet]. 1996 Dec 6 [cited 2013 Nov 28]; 274(5293):1704–7. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/8939859 PMID: 8939859
43. Va¨ha¨talo LH1, Ruohonen ST1, Ailanen L2 SE. Neuropeptide Y in noradrenergic neurons induces obe-
sity in transgenic mouse models. Neuropeptides. 2016; 55:31–7. https://doi.org/10.1016/j.npep.2015.
11.088 PMID: 26681068
44. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, et al. Association of a leucine
(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and
LDL cholesterol levels. Nat Med [Internet]. 1998 Dec [cited 2013 Nov 28]; 4(12):1434–7. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/9846584 https://doi.org/10.1038/4027 PMID: 9846584
45. Scassellati C1, Bonvicini C, Faraone SV GM. Biomarkers and attention-deficit/hyperactivity disorder: a
systematic review and meta-analyses. J Am Acad Child Adolesc Psychiatry. 2012; 51(10):1003–19.
https://doi.org/10.1016/j.jaac.2012.08.015 PMID: 23021477
46. Su Y, Foppen E, Fliers E, Kalsbeek A. Effects of intracerebroventricular administration of neuropeptide
Y on metabolic gene expression and energy metabolism in male rats. Endocrinology [Internet]. 2016
Jun 6 [cited 2016 Jul 27];en20161083. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27267712
Novel genes in severe early-onset obesity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006657 May 10, 2017 18 / 19
47. Bradbury MJ, Campbell U, Giracello D, Chapman D, King C, Tehrani L, et al. Metabotropic glutamate
receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. J Pharmacol Exp Ther
[Internet]. 2005 Apr [cited 2013 Nov 28]; 313(1):395–402. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/15590770 https://doi.org/10.1124/jpet.104.076406 PMID: 15590770
48. Bisaga A, Danysz W, Foltin RW. Antagonism of glutamatergic NMDA and mGluR5 receptors decreases
consumption of food in baboon model of binge-eating disorder. Eur Neuropsychopharmacol [Internet].
2008 Nov [cited 2013 Nov 28]; 18(11):794–802. Available from: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=2591926&tool=pmcentrez&rendertype=abstract https://doi.org/10.1016/j.
euroneuro.2008.05.004 PMID: 18573641
49. Ploj K, Albery-Larsdotter S, Arlbrandt S, Kjaer MB, Skantze PMC, Storlien LH. The metabotropic gluta-
mate mGluR5 receptor agonist CHPG stimulates food intake. Neuroreport [Internet]. 2010 Jul 14 [cited
2013 Nov 28]; 21(10):704–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20505551 https://
doi.org/10.1097/WNR.0b013e32833b4fe7 PMID: 20505551
50. Fuente-Martı´n E, Garcı´a-Ca´ceres C, Granado M, de Ceballos ML, Sa´nchez-Garrido MA´ , Sarman B,
et al. Leptin regulates glutamate and glucose transporters in hypothalamic astrocytes. J Clin Invest
[Internet]. 2012 Nov 1 [cited 2013 Nov 28]; 122(11):3900–13. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=3484452&tool=pmcentrez&rendertype=abstract
https://doi.org/10.1172/JCI64102 PMID: 23064363
51. Meek CL1, Lewis HB2, Reimann F2, Gribble FM2 PA. The effect of bariatric surgery on gastrointestinal
and pancreatic peptide hormones. Peptides. 2016; 77:28–37. https://doi.org/10.1016/j.peptides.2015.
08.013 PMID: 26344355
52. Stutzmann F, Tan K, Vatin V, Dina C, Jouret B, Tichet J, et al. Prevalence of Melanocortin-4 Receptor
Deficiency in Europeans and Their Age-Dependent Penetrance in Multigenerational Pedigrees. Diabe-
tes [Internet]. 2008 Sep 1 [cited 2016 Nov 24]; 57(9):2511–8. https://doi.org/10.2337/db08-0153 PMID:
18559663
53. Martos-Moreno GA´ , Serra-Juhe´ C, Pe´rez-Jurado LA, Argente J. Underdiagnosed Beckwith-Wiede-
mann syndrome among early onset obese children. Arch Dis Child [Internet]. 2014 Oct [cited 2016 Jul
27]; 99(10):965–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25085994
54. Rodrı´guez-Santiago B, Malats N, Rothman N, Armengol L, Garcia-Closas M, Kogevinas M, et al.
Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. Am J
Hum Genet [Internet]. 2010 Jul 9 [cited 2013 Nov 6]; 87(1):129–38. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=2896781&tool=pmcentrez&rendertype=abstract
https://doi.org/10.1016/j.ajhg.2010.06.002 PMID: 20598279
55. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, et al. A copy number variation morbid-
ity map of developmental delay. Nat Genet [Internet]. 2011 Sep [cited 2013 Nov 6]; 43(9):838–46. Avail-
able from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3171215&tool=
pmcentrez&rendertype=abstract https://doi.org/10.1038/ng.909 PMID: 21841781
56. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D, et al. The UCSC
Table Browser data retrieval tool. Nucleic Acids Res [Internet]. 2004 Jan 1 [cited 2014 Jun 4]; 32(Data-
base issue):D493–6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
308837&tool=pmcentrez&rendertype=abstract https://doi.org/10.1093/nar/gkh103 PMID: 14681465
57. Rodrı´guez-Santiago B, Brunet A, Sobrino B, Serra-Juhe´ C, Flores R, Armengol L, et al. Association of
common copy number variants at the glutathione S-transferase genes and rare novel genomic changes
with schizophrenia. Mol Psychiatry [Internet]. 2010 Oct [cited 2013 Nov 21]; 15(10):1023–33. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/19528963 https://doi.org/10.1038/mp.2009.53 PMID:
19528963
58. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of
somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol [Internet]. 2013
Mar [cited 2016 Jul 25]; 31(3):213–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23396013
https://doi.org/10.1038/nbt.2514 PMID: 23396013
Novel genes in severe early-onset obesity
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006657 May 10, 2017 19 / 19
